Iris de Heer

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick et al. · The Lancet Oncology · 2021 · 327 citations · Full text

Medicine, Oncology, Pharmacology +16

Transcriptome analysis reveals tumor microenvironment changes in glioblastoma

Youri Hoogstrate, Kaspar Draaisma, Santoesha A. Ghisai et al. · Cancer Cell · 2023 · 249 citations · Full text

Medicine, Cancer Biology, Oncology +17

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Martin J. van den Bent, Martin Klein, Marion Smits et al. · The Lancet Oncology · 2018 · 130 citations · Full text

Medicine, Oncology, Pharmacology +16

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

C. Mircea S. Tesileanu, Marc Sanson, Wolfgang Wick et al. · Clinical Cancer Research · 2022 · 72 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

C. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson et al. · Neuro-Oncology · 2021 · 63 citations · Full text

Medicine, Oncology, Pathology +17